Parmax Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹12 crore and net profit of ₹0.17 crore for the September 2026 quarter.
Parmax Pharma (BSE: PARMAX) closed at ₹135.10 on 16 Nov 2026, up 322.2% over the past year. Its market capitalisation is ₹93 crore.
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.